Background: The GenoType® MTBDRsl assay (Hains, Lifesciences, Germany) is a new rapid
INTRODUCTION
The increasing problem of multidrug-resistant tuberculosis (MDR-TB) caused by M. tuberculosis strains that are resistant to isoniazid (INH) and rifampicin (RIF) and the em ergence of extensively drug resistant tubercul osis (XDR-TB), defined as MDR-TB wi th additional resistance to any fluoroquinolon (FLQ) and to at least one of three injectable secondline drugs, (kanamycin [KAN] , amikacin [AK] , and/or capreomycin [CAP] ) has become a global health problem, threatening the success of TB control programmes (1,2). The WHO developed guidelines for drug susceptibility testing (DST) for first and second-line anti-TB drugs on Lowenstein-Jensen (LJ) medium or Middlebrook agar using the proportion method. However, DST of M. tuberculosis to second-line drugs is difficult, expensive, and not well standardised. In addition results are only available within 3 to 6 weeks. Therefore, there is a major interest in rapid molecular detection methods for resistance to these drugs.
The GenoType® MTBDRsl assay (Hain Lifesciences, Germany) was developed for rapid detection of resistance against second-line drugs (3) . The assay uses a multiplex PCR and reverse hybridisation to identify M. tuberculosis and relevant mutations in genes, gyrA, rrs, and embB that confer resistance to FLQ, CAP/AK/KAN/viomycin (VIO) and ethambutol (EMB), respectively (3) . Previous studies reported that the majority of FLQ-resistant M. tuberculosis isolates had mutations in the quinolone resistance determining region (QRDR) in the gyrA gene (mutations mostly in codon A90, 91 and D94 and, more rarely, G88 and S91), and less frequently in gyrB gene (4, 5, 6) . Resistance to CAP, KAN, and AK has been shown to be associated with mutations at positions 1401 and 1402 and position 1484 in the rrs gene (7, 8) .
Mutations 1401 and 1484 were found to cause high-level resistance to all drugs, whereas 1402 causes resistance to only CAP and KAN. In addition, the tlyA gene, which encodes a putative rRNA methyltransferase, was reported to confer resistance to CAP (9) . Ethambutol resistance is reported to be most frequently associated with mutations in the embCAB operon. However, 50% to 70% of EMB resistant M. tuberculosis isolates contain missense mutations in the embB gene with the majority (47 to 60%) of the M. tuberculosis strains carrying mutations at codon 306 (10, 11) .
The aim of the study was to evaluate the performance of the MTBDRsl assay for the detection of of l ox aci n (OF X), KA N, CA P an d EMB resi stan ce i n a hi gh -TB b urden area. Th e resul ts obtained were compared with those of the standard agar proportion method which is performed in parallel with the MTBDRsl assay.
MATERIALS AND METHODS

Study setting and clinical isolates
The study was conducted at Diagnostic Microbiology Laboratory at Tshwane Academic Division located in Pretoria, South Africa. A total of 342 consecutive MDR-TB isolates were collected from the National Health Laboratory Service (NHLS) Diagnostic Microbiology laboratory at the Medical University of Southern Africa. The laboratory receives specimens from the surrounding clinics and hospitals in the referring provinces of Limpopo, North-West and Mpumalanga, a geographic area with high incidence of TB. All isolates were freshly sub-cultured on Middlebrook agar before being tested by the different methods.
Drug susceptibility testing
Drug susceptibility testing was done for OFX, KAN, CAP and EMB using the agar proportion method. An MDR-TB isolate was classified as resistant when the colonies on the drugcontaining quadrant appeared 1% compared to the drug-free control quadrant.
GenoType® MTBDRsl assay
The DNA of MDR-TB isolates was extracted according to a method described previously (12) .
MTBDRsl assay was performed as described by the manufacturer. Either the absence of a wildtype band or the presence of a mutant band was an indicative of a resistant isolate.
DNA sequencing of discrepant results
All discrepant isolates were sequenced to evaluate discrepancies between MTBDRsl and agar proportion method. The primers used for amplification and sequencing are shown in Table 1 .
Statistical analysis
The sensitivity, specificity, positive and negative predictive values was calculated for each drug compared to the gold standard agar proportion method. The agreement between the two methods was determined by the κ statistic. The κ value, a measure of test reliability, was interpreted as follows: < 0.2, poor; 0.21 to 0.4, fair; 0.41 to 0.6, moderate; 0.61 to 0.8, good; ≥ 0.81, excellent (13) .
RESULTS
Of the total 342 isolates tested by the MTBDRsl assay, 336 (98.2%) gave interpretable results. In 6 isolates, no TUB band was observed and these isolates were excluded from the analysis. No contamination was observed in the negative controls. A total of 21/336 (6.3%) isolates met the criteria for the classification as XDR-TB by the agar proportion method and 8/336 (2.4%) by the MTBDRsl assay. Turnaround times for DST ranged from 6 to 21 days (median, 11 days) for the agar proportion method and from 2 to 3 days (median, 2 days) for the MTBDRsl assay. The DST results of the MTBDRsl assay as compared to the agar proportion method are shown in Table 2 .
Ofloxacin resistance: The sensitivity and specificity of the MTBDRsl assay for OFX resistance was 70.3% and 97.7%, respectively (Table 3 (Table 4) .
Among the 33/336 OFX-resistant isolates by MTBDRsl assay, the gyrA MUT 3C/D94G was the most prevalent mutation occurring in 14/33 (42.4%) isolates followed by the gyrA MUT 3D/D94H (10/33; 30.3%), gyrA MUT 1/A90V mutation (1/33; 3.0%) and gyrA MUT 3B band/D94Y (1/33; 3.0%). In 5 of 33 isolates (15.2%) both gyrA MUT 3C/D94G and gyrA MUT 1/A90V were present. For 2 isolates (2/33; 6.1%) resistance was indicated by omission of wildtype pattern.
Kanamycin and/or capreomycin resistance: In 4/336 (1.2%) isolates, the rrs gene control band was absent. Similar results were obtained after repeating the assay and hence, these isolates were excluded from the analysis. The sensitivity and specificity of the MTBDRsl assay was 25.0% and 98.7% for KAN, 21.2% and 98.7% for CAP, respectively (Table 3) .
A total of 304/332 (91.6%) were phenotypically susceptible to KAN and of these 300/304 (98.7%) showed wild-type patterns with the MTBDRsl assay and the remaining 4 (1.3%) had mutation in the rrs gene. DNA sequencing confirmed the presence of mutations in all 4 isolates.
Of the 332 isolates, 28 (8.4%) were phenotypically resistant to KAN and only 7 (25.0%) of these isolates had mutations by the MTBDRsl assay, while the remaining 21 (75.0%) had wild-type patterns. Among the 21 discrepant isolates, 6 isolates (including 3 phenotypically XDR-TB isolates) had mutation in the rrs gene by DNA sequencing and were not detected by the MTBDRsl assay (Table 4) (Table 4 ). This mutation was not detected by MTBDRsl assay as the tlyA gene is not included in the assay.
Of the 11 KAN/CAP resistant isolates by MTBDRsl assay, 1/11 (9.1%) had rrs MUT 1/A1401G and the other 1/11 (9.1%) had rrs MUT 2/A1484T mutation. The remaining 9/11 (81.8%) were resistant by absence of wild-type patterns.
Ethambutol resistance: In 20/336 (5.9%) of the isolates tested for EMB, both the wild-type and mutant EMB bands were observed, suggesting heteroresistance and thus were not included in the analysis. The sensitivity and specificity of the MTBDRsl assay for detection of EMB resistance was 56.3% and 56.0% respectively (Table 3) . Of the 316 isolates, 268 (84.8%) were phenotypically susceptible to EMB and of these 150 (56.0%) showed wild-type pattern and the remaining 118 (44.0%) showed mutations with the MTBDRsl assay. Forty-eight of the 316 isolates (15.2%) were phenotypically resistant to EMB. However, only 27 (56.3%) showed mutations with the MTBDRsl assay while the remaining 21 (44.0%) showed wild-type patterns.
The discrepant isolates were sequenced in the embB306 gene to evaluate discrepancies. Of the 118 isolates resistant by the MTBDRsl assay, only 67 (56.8%) isolates had mutation with the DNA sequencing, while the remaining 51 (43.2%) isolates had no mutation (Table 4) .
Of the 21 isolates susceptible to EMB by MTBDRsl assay, mutation was detected in 9 (42.9%)
isolates by DNA sequencing. The remaining 12 (57.1%) isolates had wild-type patterns. The most prevalent mutation of the 145 EMB resistant isolates with MTBDRsl assay was embB MUT 1B/M306V (101/145; 69.7%), followed by embB MUT 1A/M3061 (36/145; 24.8%) and the remaining isolates (8/145; 5.5%) were resistant by absence of wild-type patterns.
DISCUSSION
In this study the largest number of isolates (342 MDR-TB) was used to evaluate MTBDRsl assay (3, 14, 15) . A good agreement (Kappa=0.73) was found between the MTBDRsl assay and the agar proportion method for OFX, with a sensitivity of 70.3%. Previous studies have reported similar sensitivity values for the MTBDRsl assay for detecting FLQ-resistance, ranging from 70% to 87% (3, 14, 15, 16) . A significant finding of this study, DNA sequencing identified mutation in 8/11 phenotypically resistant to OFX in the in the gyrA gene (2/8 had additional mutation in gyrB), while 1/11 (phenotypically XDR-TB isolate) had mutation only in the gyrB gene.
Similarly, Mokrousov et al. (6) found OFX-resistant isolates with only gyrB mutations and one of these isolate was an XDR-TB strain. Given these findings, genotypic testing for OFX resistance should not be limited to the analysis of the gyrA gene but should also include the gyrB gene. Furthermore, inclusion a bigger region of the gyrA gene could have picked up 8/11 (72.7%), with a resultant increase sensitivity to 92.0%.
In 3 phenotypically OFX-resistant isolates, no mutation was found in gyrA or gyrB gene.This finding suggests mutation in another target gene or the use of other mechanisms such as decreased cell-wall permeability to drug, drug efflux pump, or even drug inactivation (17) .
Although the specificity of the MTBDRsl assay for the detection of KAN/CAP resistance was excellent (98.7% and 98.7%), the sensitivity was low (25.0% and 21.2%). Previous studies reported higher sensitivity (77% to 100% for KAN and 80.0% to 86.7% for CAP) (3, 14, 15) .
However, these studies tested small number of isolates (5-13 isolates) and larger number of isolates need to be tested to assess sensitivity accurately. Recently, Huang et al. (16) tested 234 MDR isolates using MTBDRsl assay and found low sensitivity (43.2%) for detecting KAN resistance.
The low sensitivity of KAN/CAP in this study could be due to other mutations associated with resistance to these drugs. The MTBDRsl assay uses only one gene (rrs) for the detection of KAN and CAP resistance. The tlyA gene is reported to cause CAP resistance (9) and the promoter region of eis gene, which encodes an aminoglycoside acetyltransferase, are associated with lowlevel KAN resistance (18) . It has been reported that tlyA mutations are mainly associated in vitro selected CAP-resistant mutants and are rare in clinical isolates of M. tuberculosis (9, 19, 20) .
However, in this was not the case in this study, as 20/26 of the discrepant results which were pheonotypically resistant to CAP and 3/4 CAP-resistant by MTBDRsl assay had mutation in the tlyA gene. Therefore, the role of tlyA gene in CAP resistant clinical isolates should be further investigated.
In 15 phenotypically KAN-resistant isolates and 6 phenotypically CAP-resistant isolates, no mutation was detected in either rrs or tlyA genes. Unidentified mutations associated with CAP and KAN resistance could explain this finding. Further work is needed to determine the mechanism of the unexplained KAN and CAP resistance as resistance to one of these drugs is a marker for XDR-TB.
The sensitivity of MTBDRsl assay for detection of EMB resistance in this study was low (56.3%). Similarly, previous studies reported a sensitivity ranging from 56% to 69% (3, 14, 15, 16) . EMB is known to be a problematic drug to be tested and often yields less reproducible results (21, 22) . Of the 118 resistant by MTBDRsl a s s a y , D N A s e q u e n c i n g identified mutation in embB306 gene in only 67/118 (56.8%) isolates. The discrepancy could be due to the shorter region of the embB306 gene analysed by sequencing. Thus, some of the mutations could lie outside the region anaysed in this study. The limitation of the study; the discrepant results were not repeated by MTBDRsl assay to rule out the non-specific hybridisation, however no contamination was observed in negative controls.
In this study, 20/336 (5.9%) isolates showed heteroresistant for the EMB gene. Heteroresistance of M. tuberculosis is considered a precursor to development of full resistance (23) . This highlights the important advantage of genotypic over the phenotypic methods, as genotypic methods are able to detect mixed strains.
The low performance of the MTBDRsl assay in this study was not unique since molecular methods detect only mutations that are screened for, while phenotypic tests detect resistance independent of the underlying mechanism and in addition not all mutations conferring resistance to second-line anti-TB drugs are known especially for KAN, CAP and EMB. In addition the prevalence of certain strains with specific mutation may vary in different geographical areas and thus will affect the test performance. On the other hand significant challenges exist in phenotypic susceptibility testing to second-line drugs. Although standard protocols exist, phenotypic susceptibility testing to second-line drugs is often unreliable and inaccurate, with poor clinical predictive values (24) .
In conclusion, the MTBDRsl assay showed a lower sensitivity in this study as compared to previous studies. The sensitivity of the assay was variable among the drugs tested. The MTBDRsl assay performed favourably to the agar proportion method for OFX; however the assay was less sensitive for detection of KAN/CAP resistance and demonstrated low sensitivity and specificity for EMB resistance. The resolution of discrepant isolates with DNA sequencing has shown that the inclusion of gyrB gene and covering bigger region of gyrA may improve the sensitivity of the assay for detection of FLQ resistance. In addition inclusion of other genes such as the tlyA for detection CAP resistance and other regions of the embB gene as well as other targets associated with EMB resistance could improve the performance of the assay. OFX=ofloxacin, KAN=kanamycin, CAP=capreomycin, EMB=ethambutol ,S=susceptible, R=resistant 
